JT001 (VV116) for the Treatment of COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

1,369

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
Mild to Moderate COVID-19
Interventions
DRUG

JT001

JT001 administered orally in tablet form every 12 hours for 5 days

DRUG

Placebo

Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days

Trial Locations (9)

310022

Shulan (Hangzhou) Hospital, Hangzhou

Unknown

Fuzhou Pulmonary Hospital Of Fujian, Fuzhou

The third people's hospital of Shenzhen, Shenzhen

Wuhan Infections Diseases Hospital, Wuhan

The Fourth Hospital in Inner Mongolia, Hohhot

The Sixth People's Hospital of ShenYang, Shenyang

Shandong Public Health Clinical Center, Jinan

Shanghai Public Health Clinical Center, Shanghai

Quzhou People's Hospital, Quzhou

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Shanghai Vinnerna Biosciences Co., Ltd.

INDUSTRY